Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2003 Jul-Aug;5(4):249-53.
doi: 10.1111/j.1524-6175.2003.01960.x.

Comparative effect of lercanidipine, felodipine, and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercanidipine in Adults (LEAD) Study

Affiliations
Clinical Trial

Comparative effect of lercanidipine, felodipine, and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercanidipine in Adults (LEAD) Study

Roberta Romito et al. J Clin Hypertens (Greenwich). 2003 Jul-Aug.

Abstract

This multicenter, double-blind, parallel-group study compared the effects of three dihydropyridine calcium channel blockers (lercanidipine, felodipine, and nifedipine gastrointestinal therapeutic system) on blood pressure and heart rate in 250 patients with mild to moderate hypertension (diastolic blood pressure > or =95 and 109 mm Hg). Patients were randomized to 4 weeks of treatment with once-daily doses of lercanidipine 10 mg, felodipine 10 mg, or nifedipine gastrointestinal therapeutic system 30 mg. After 4 weeks of treatment, the dose was doubled in nonresponding patients. At 8 weeks, no significant differences in blood pressure were observed among the three groups. Increases in heart rate in all three groups induced by stressful conditions before and after treatment were not exacerbated during active treatment. The incidence of adverse drug reactions was lower in the lercanidipine and nifedipine groups than in the felodipine group (p<0.05); in particular, the incidence of edema for lercanidipine was 5.5% vs. 13% for felodipine and 6.6% for nifedipine.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Kaplan NM. Calcium entry blockers in the treatment of hypertension. JAMA. 1989;262:817–823. - PubMed
    1. Opie LH. Clinical Use of Calcium Channel Antagonist Drugs. 2nd ed. Boston , MA : Kluwer Academic Publishers; 1990.
    1. Staessen JA, Fagard R, Thijs L, et al., for the Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350:757–764. - PubMed
    1. Morgan TO, Anderson AI, MacInnis RJ. ACE inhibitors, beta‐blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am J Hypertens. 2001;14:241–247. - PubMed
    1. Barchielli M, Dolfini E, Farina P, et al. Clinical pharmacokinetics of lercanidipine. J Cardiovasc Pharmacol. 1997;29(suppl 2):S1–S15.

MeSH terms